Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ocrelizumab SC in Multiple Sclerosis
NCT07667322Phase 1Active, not recruiting
- Sponsor
- Roche
- Start
- Dec 2024
- Primary completion
- Feb 2028
- Countries
- 4
01
Overview
Phase 1, open-label, single-arm trial of ocrelizumab in multiple sclerosis (MS), sponsored by Roche. Primary endpoint: Number of Participants With Adverse Events at 168 weeks. Started Dec 2024; status: active, not recruiting.
02
Drugs
ocrelizumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT07667322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07667322.